TRIAL DETAIL
Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors
|
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 06/11/2007 |
Age of Trial (yrs) 17.5 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
mTOR inhibitor
PI3K inhibitor |
|||
Strategy: |
Block related tumor signal paths |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
XL765-001 |
|||
Sponsor: |
Exelixis |
|||
Patient Contact: |
Exelixis Contact Line |
|||
Contact email: |
||||
Contact Phone: |
866-939-4041 |
|||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
The purpose of this study is to determine the safety and tolerability of XL765. XL765 is a new chemical entity that inhibits the kinases PI3K and mTOR. In preclinical studies, inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells, whereas inactivation of mTOR has been shown to inhibit the growth of tumor cells. |
|||
Trial Links |
Trial Results |
Drug Information |
| Exelixis drug page |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
4100 John R |
Detroit |
MI |
48201 |
USA |
|
4319 Medical Dr. |
San Antonio |
TX |
78229 |
USA |
|
119-129 |
Barcelona |
08035 |
Spain |